SCHEMBL31599360

SCHEMBL31599360

C=CC(=O)Nc1cnc2c(c1)cc(C)n2-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 2/20 0.53
F13A1 P00488 1/20 0.41
TGM1 P22735 1/20 0.41
EGFR P00533 9/20 0.41
FLT3 P36888 5/20 0.41
NR3C1 P04150 4/20 0.40
GSTO1 P78417 1/20 0.40
BLK P51451 3/20 0.40
BTK Q06187 3/20 0.40
KDR P35968 1/20 0.39
TEK Q02763 1/20 0.39
MAOB P27338 1/20 0.39
ERBB2 P04626 1/20 0.39
TEC P42680 1/20 0.39
TXK P42681 1/20 0.39
BMX P51813 1/20 0.39
JAK3 P52333 1/20 0.39
ERBB4 Q15303 1/20 0.39
FGFR1 P11362 2/20 0.39
FGFR4 P22455 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27201005 0.82 TGM2 (0.56) TGM2F13A1TGM1EGFRGSTO1
SCHEMBL31336744 0.82 TGM2 (0.53) TGM2F13A1TGM1EGFRNR3C1
SCHEMBL26220773 0.82 TGM2 (0.53) TGM2F13A1TGM1EGFRNR3C1
SCHEMBL26220771 0.82 TGM2 (0.53) TGM2F13A1TGM1EGFRNR3C1
SCHEMBL31336535 0.82 TGM2 (0.53) TGM2F13A1TGM1EGFRNR3C1
SCHEMBL25388073 0.79 TGM2 (0.50) TGM2F13A1TGM1EGFRNR3C1
SCHEMBL30590826 0.79 TGM2 (0.50) TGM2F13A1TGM1EGFRNR3C1
SCHEMBL30590830 0.78 NR3C1 (0.50) TGM2F13A1TGM1EGFRNR3C1
SCHEMBL25386283 0.78 NR3C1 (0.50) TGM2F13A1TGM1EGFRNR3C1
SCHEMBL25041682 0.77 TGM2 (0.48) TGM2F13A1TGM1EGFRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171451-A1 NOVEL HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2025-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171451-A1 NOVEL HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME CYP4A11, CYP11B2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 TGM2 4139/4885F13A1 3048/4885TGM1 2923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.